Madrigal Pharma (MDGL) Misses Q3 EPS by 44c

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($5.34), $0.44 worse than the analyst estimate of ($4.90). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• Ecolab pops as Citi sees improving setup into Q2 earnings